AR013118A1 - Compuestos agonistas de prostaglandinas, procedimiento para tratar, aumentar y mantener un trastorno que produce perdida de la masa osea,composiciones farmaceuticas y el estuche para dicho compuesto - Google Patents
Compuestos agonistas de prostaglandinas, procedimiento para tratar, aumentar y mantener un trastorno que produce perdida de la masa osea,composiciones farmaceuticas y el estuche para dicho compuestoInfo
- Publication number
- AR013118A1 AR013118A1 ARP980102993A ARP980102993A AR013118A1 AR 013118 A1 AR013118 A1 AR 013118A1 AR P980102993 A ARP980102993 A AR P980102993A AR P980102993 A ARP980102993 A AR P980102993A AR 013118 A1 AR013118 A1 AR 013118A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- optionally
- prostaglandin agonists
- pharmaceutical compositions
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000000988 bone and bone Anatomy 0.000 title 1
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 239000000556 agonist Substances 0.000 abstract 6
- 150000003180 prostaglandins Chemical class 0.000 abstract 5
- -1 propylene, propenylene Chemical group 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052757 nitrogen Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 239000011593 sulfur Chemical group 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se refiere a agonistas de prostaglandinas, a procedimientos para utilizar dichos agonistas de prostaglandinas, a composiones farmacéuticasque contienen dichos agonistas de prostaglandinas y a estuches que contienen dichos agonistas de prostaglandinas. Los agonistas de prostaglandinas sonutiles para el tratamiento de trastornos oseos, incluyendo las osteoporosis. Donde dicho agonista es or ejemplo un compuesto de formula (I), unprofármaco del mismo o las sales farmacéuticamente aceptables de dichos compuestos y profármacos en la que: A es hidrogeno o hidroxi; B es propileno,propenileno o propinileno; Q es propileno, -CH2OCH2-, tiazolilo, piridilo, fenilo o tienilo; Z es carboxilo, alcoxicarbonil C1-6, tetrazolilo, 1,2,4-oxadiazolilo o 5-oxo-1,2,4-oxadiazolilo; K es etileno o etenileno; L es un enlace o -CO-; M es -Ar, -Ar1-V-Ar2, -Ar1-S-Ar2 o -Ar1-O-Ar2, siendo Ar y Ar1o (1) cada uno de ellos independientemente un anillo de cinco a ocho elementos totalmente insaturados y que opcionalmente tiene de uno a cuatro heteroátomosseleccionados independientemente entre oxígeno, azufre y nitrogeno, o un anillo bicíclico constituido por dos anillos de cinco y/o seis elementoscondensados, parcialmentesaturados, totalmente saturados o totalmente insaturados, considerados independientemente, que opcionalmente tienen de unoa cuatro heteroátomos seleccionados independientemente entre nitrogeno, azufre y oxígeno, o un anillo tricíclico constituido por tres anillos decinco y/o seis elementos condensados, parcialmente saturados, totalmente saturados o totalmente insaturados, considerados independientemente, queopcionalmente tiene de uno a cuatro heteroátomos seleccionadosindependientemente entre nitrogeno, azufre y oxígeno, teniendo opcionalmente
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5057597P | 1997-06-23 | 1997-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR013118A1 true AR013118A1 (es) | 2000-12-13 |
Family
ID=21966050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980102993A AR013118A1 (es) | 1997-06-23 | 1998-06-22 | Compuestos agonistas de prostaglandinas, procedimiento para tratar, aumentar y mantener un trastorno que produce perdida de la masa osea,composiciones farmaceuticas y el estuche para dicho compuesto |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6531485B2 (es) |
| AP (1) | AP9801269A0 (es) |
| AR (1) | AR013118A1 (es) |
| AU (1) | AU7349298A (es) |
| CO (1) | CO5080735A1 (es) |
| GT (1) | GT199800083A (es) |
| HR (1) | HRP980356A2 (es) |
| MA (1) | MA26514A1 (es) |
| PA (1) | PA8452701A1 (es) |
| TN (1) | TNSN98104A1 (es) |
| WO (1) | WO1998058911A2 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000051980A1 (en) | 1999-03-05 | 2000-09-08 | The Procter & Gamble Company | C16 unsaturated fp-selective prostaglandins analogs |
| IL141120A0 (en) | 2000-01-31 | 2002-02-10 | Pfizer Prod Inc | Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure |
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| EP1507858B1 (en) * | 2002-05-29 | 2008-09-17 | DSM IP Assets B.V. | Method for the purification of a rhizomucor aspartic protease |
| JP2006021998A (ja) * | 2002-07-18 | 2006-01-26 | Ono Pharmaceut Co Ltd | Ｅｐ２アゴニストを有効成分とする月経困難症治療剤 |
| ES2393321T3 (es) | 2002-10-10 | 2012-12-20 | Ono Pharmaceutical Co., Ltd. | Promotores de la producción de factores de reparación endógenos |
| EP2422814A1 (en) | 2003-07-25 | 2012-02-29 | Ono Pharmaceutical Co., Ltd. | Remedy for cartilage-related diseases |
| JP4893999B2 (ja) | 2004-10-22 | 2012-03-07 | 小野薬品工業株式会社 | 吸入用医薬組成物 |
| US7091231B2 (en) * | 2004-12-10 | 2006-08-15 | Allergan, Inc. | 12-Aryl prostaglandin analogs |
| BRPI0605926A2 (pt) | 2005-01-14 | 2009-05-26 | Allergan Inc | ciclopentanos substituìdos ou ciclopentanonas como agentes terapêuticos |
| NZ563863A (en) | 2005-06-03 | 2011-02-25 | Ono Pharmaceutical Co | Agent for regeneration and/or protection of nerves |
| GB0518494D0 (en) * | 2005-09-09 | 2005-10-19 | Argenta Discovery Ltd | Thiazole compounds |
| US7323591B2 (en) | 2006-01-10 | 2008-01-29 | Allergan, Inc. | Substituted cyclopentanes or cyclopentanones as therapeutic agents |
| JP2009541340A (ja) * | 2006-06-20 | 2009-11-26 | アラーガン インコーポレイテッド | 治療用化合物 |
| EP2069295B1 (en) * | 2006-07-10 | 2013-12-18 | Allergan, Inc. | Substituted cyclopentane derivatives as therapeutic agents |
| BRPI0714885B8 (pt) * | 2006-07-11 | 2021-05-25 | Allergan Inc | compostos terapêuticos e seu uso |
| EP2170345B1 (en) * | 2007-07-03 | 2013-03-06 | Allergan, Inc. | Therapeutic substituted cyclopentanes for reducing intraocular pressure |
| US7737140B2 (en) * | 2008-04-24 | 2010-06-15 | Allergan, Inc. | Therapeutic compounds |
| WO2009137412A1 (en) * | 2008-05-09 | 2009-11-12 | Allergan, Inc. | Therapeutic compounds |
| US8592413B2 (en) | 2008-05-15 | 2013-11-26 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
| WO2014069401A1 (ja) | 2012-10-29 | 2014-05-08 | 株式会社カルディオ | 肺疾患特異的治療剤 |
| US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
| KR102674146B1 (ko) * | 2020-04-21 | 2024-06-10 | 구미아이 가가쿠 고교 가부시키가이샤 | 메탄 생성 저해제 조성물 및 메탄 생성의 억제 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3888905A (en) | 1969-02-17 | 1975-06-10 | Searle & Co | Prostaglandin intermediates and optically active isomers thereof |
| US3980700A (en) | 1971-10-07 | 1976-09-14 | G. D. Searle & Co. | Prostaglandin intermediates and optically active isomers thereof |
| DE2434133C2 (de) * | 1974-07-12 | 1987-03-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | 15,15-Äthylendioxy-Prostansäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| GB1521688A (en) | 1974-11-01 | 1978-08-16 | May & Baker Ltd | Cyclopentane derivatives |
| US3932389A (en) | 1974-12-11 | 1976-01-13 | Pfizer Inc. | 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins |
| US4197407A (en) | 1977-03-30 | 1980-04-08 | American Cyanamid Company | Prostenoic acids and esters |
| US4097601A (en) | 1977-08-26 | 1978-06-27 | Pfizer Inc. | Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins |
| HN1996000101A (es) | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
-
1998
- 1998-06-04 US US09/446,099 patent/US6531485B2/en not_active Expired - Fee Related
- 1998-06-04 AU AU73492/98A patent/AU7349298A/en not_active Abandoned
- 1998-06-04 WO PCT/IB1998/000866 patent/WO1998058911A2/en active Application Filing
- 1998-06-08 PA PA19988452701A patent/PA8452701A1/es unknown
- 1998-06-18 AP APAP/P/1998/001269A patent/AP9801269A0/en unknown
- 1998-06-18 GT GT199800083A patent/GT199800083A/es unknown
- 1998-06-22 AR ARP980102993A patent/AR013118A1/es not_active Application Discontinuation
- 1998-06-22 TN TNTNSN98104A patent/TNSN98104A1/fr unknown
- 1998-06-22 MA MA25129A patent/MA26514A1/fr unknown
- 1998-06-23 CO CO98035644A patent/CO5080735A1/es unknown
- 1998-06-23 HR HR60/050,575A patent/HRP980356A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20030008895A1 (en) | 2003-01-09 |
| AU7349298A (en) | 1999-01-04 |
| HRP980356A2 (en) | 1999-02-28 |
| MA26514A1 (fr) | 2004-12-20 |
| TNSN98104A1 (fr) | 2005-03-15 |
| US6531485B2 (en) | 2003-03-11 |
| AP9801269A0 (en) | 1999-12-18 |
| GT199800083A (es) | 1999-12-10 |
| CO5080735A1 (es) | 2001-09-25 |
| WO1998058911A2 (en) | 1998-12-30 |
| PA8452701A1 (es) | 2000-05-24 |
| WO1998058911A3 (en) | 1999-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR013118A1 (es) | Compuestos agonistas de prostaglandinas, procedimiento para tratar, aumentar y mantener un trastorno que produce perdida de la masa osea,composiciones farmaceuticas y el estuche para dicho compuesto | |
| AR008829A1 (es) | Derivados 6,6- o 6,7 biciclicos sustituidos que contienen pirido o pirimido como agentes antagonistas para el tratamiento de enfermedades gastrointestinales, inflamatorias y del snc, y composicion farmaceutica | |
| AR029634A1 (es) | Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento | |
| CO4910163A1 (es) | Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas | |
| ES2116131T3 (es) | Derivados de naftaleno, su procedimiento de preparacion y productos intermediarios adecuados, y las composiciones farmaceuticas que los contienen. | |
| PA8503301A1 (es) | Compuestos para el tratamiento de la isquemia | |
| CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| ECSP014097A (es) | Derivados de tiofeno utiles como agentes anticancerosos | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| PA8580301A1 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
| HK1120725A1 (en) | Tetrahydro-beta-carbolin-sulfonamide derivatives as 5-ht6ligands | |
| GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
| UY26130A1 (es) | Compuestos para tratar la obesidad | |
| MXPA04000456A (es) | Analogos de prostaglandina como agonistas del receptor ep4. | |
| PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
| CO5601002A2 (es) | Inhibidores de la acc | |
| EE200100487A (et) | Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena | |
| ATE309999T1 (de) | Blutplättchen-adp-rezeptor-inhibitoren | |
| AR003453A1 (es) | Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores | |
| ATE284388T1 (de) | Cyclpentanoindole, mischungen derartige verbindungen enthaltend und behandlungsmethoden | |
| ECSP055599A (es) | AGONISMO DEL RECEPTOR DE 5HT2a PARA EL TRATAMIENTO DE DISFUNCION TERMORREGULADORA | |
| CO5640104A2 (es) | Derivados de aminoisoxazol activos como inhibidores de quinasa | |
| HN1998000074A (es) | Derivados de macrolidos c-4 sustituidos | |
| NO20024521L (no) | Heterocyklisk sidekjede-inneholdende metalloproteaseinhibitorer | |
| NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |